Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Eli lilly and company crawled time : 14:30 save search
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
Published: 2024-03-14 (Crawled : 14:30) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
|
| O: -1.45%
H: 0.04%
C: -6.49%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.94%
H: 0.4%
C: -0.55%
pharmaceuticals
Philip Johnson to Retire as Lilly Treasurer
Published: 2024-02-09 (Crawled : 14:30) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 1.39%
C: 0.63%
FDA Roundup: December 5, 2023
Published: 2023-12-05 (Crawled : 14:30) - fda.gov
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
fda
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Published: 2023-12-04 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: 0.0%
biopharma acquire
The Top 12 Biopharma Companies Hiring Now
Published: 2023-09-13 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
companies biopharma
Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.68%
H: 0.48%
C: -0.19%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: -3.7%
conference breast presentation cancer pharmaceuticals research
Entos Pharmaceuticals Announces Senior Leadership Appointments to Expand Executive Team and Accelerate Growth
Published: 2022-03-03 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.08%
H: 1.86%
C: 1.5%
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 1.9%
H: 1.63%
C: -2.33%
als ces cel growth
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
Published: 2022-03-01 (Crawled : 14:30) - ir.pulmatrix.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
PULM | $2.0 2.04% 2.0% 12K
|
Health Technology
|
| O: 1843.63%
H: 2.17%
C: -4.67%
matrix expansion
Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility
Published: 2022-02-22 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.46%
H: 0.69%
C: -0.03%
therapeutics
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.47%
H: 5.06%
C: -4.11%
covid-19 covid report phase 3 sabizabulin
180 Degree Capital Corp. Portfolio Company, D-Wave Systems, Inc., Announces Intent to Become a Public Company Through a Merger With DPCM Capital, Inc. and Provides an Update on Legacy Private Portfolio Monetization Efforts
Published: 2022-02-08 (Crawled : 14:30) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
TURN | $3.98 -0.25% 4.8K
|
Finance
|
| O: 0.97%
H: 8.67%
C: 5.98%
ces system one merge
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.37%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 2.21%
H: 4.99%
C: 4.05%
verzenio trial collaboration phase 3
NCCN Announces Funding for Lung and Thyroid Cancer Quality Projects, in Collaboration with Lilly
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
funding collaboration cancer
RION Appoints Alisa Lask as Chief Commercial Officer
Published: 2022-01-14 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
NEPH | $2.03 2.93% 9.2K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -2.96%
CLGN | $5.22 -2.54% 1.2K
|
Health Technology
|
| O: 4.18%
H: 0.0%
C: 0.0%
commercialization
Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
Published: 2021-12-21 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
RIGL | $1.07 1.91% 1.87% 810K
|
Health Technology
|
| O: 2.25%
H: 0.37%
C: -0.73%
treatment trial chronic immune phase 3
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
NKTR | News | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
nktr-255 ema car-t therapeutics therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.